Have a feature idea you'd love to see implemented?
Let us know!
MAIA MAIA Biotechnology Inc
Price (delayed)
$2.905
Market cap
$69.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.63
Enterprise value
$57.87M
We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In
Highlights
MAIA Biotechnology's quick ratio has soared by 95% from the previous quarter and by 18% YoY
MAIA's equity has surged by 155% since the previous quarter but it has dropped by 54% year-on-year
MAIA Biotechnology's net income has plunged by 59% YoY and by 18% from the previous quarter
The EPS has declined by 3.8% year-on-year and by 3.2% since the previous quarter
Key stats
What are the main financial stats of MAIA
Market
Valuations
Earnings
Shares outstanding
23.91M
Market cap
$69.45M
Enterprise value
$57.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
20.06
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$28.08M
EBITDA
-$28.08M
Free cash flow
-$15.42M
Per share
Balance sheet
Liquidity
EPS
-$1.63
Free cash flow per share
-$0.69
Book value per share
$0.14
Revenue per share
$0
TBVPS
$0.54
Total assets
$12.02M
Total liabilities
$8.86M
Debt
$0
Equity
$3.16M
Working capital
$8.51M
Debt to equity
0
Current ratio
3.42
Quick ratio
3.3
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-318.1%
Return on equity
-18,051.7%
Return on invested capital
N/A
Return on capital employed
-330%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MAIA stock price
How has the MAIA Biotechnology stock price performed over time
Intraday
6.8%
1 week
9.21%
1 month
3.38%
1 year
45.25%
YTD
148.29%
QTD
3.38%
Financial performance
How have MAIA Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.1M
Net income
-$28.08M
Gross margin
N/A
Net margin
N/A
MAIA Biotechnology's net income has plunged by 59% YoY and by 18% from the previous quarter
MAIA Biotechnology's operating income has decreased by 5% YoY but it has increased by 4.3% from the previous quarter
Growth
What is MAIA Biotechnology's growth rate over time
Valuation
What is MAIA Biotechnology stock price valuation
P/E
N/A
P/B
20.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 3.8% year-on-year and by 3.2% since the previous quarter
MAIA's equity has surged by 155% since the previous quarter but it has dropped by 54% year-on-year
Efficiency
How efficient is MAIA Biotechnology business performance
The return on assets has dropped by 108% year-on-year and by 12% since the previous quarter
Dividends
What is MAIA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MAIA.
Financial health
How did MAIA Biotechnology financials performed over time
MAIA's total assets is 36% greater than its total liabilities
MAIA Biotechnology's total liabilities has soared by 161% YoY but it has decreased by 39% from the previous quarter
MAIA Biotechnology's quick ratio has soared by 95% from the previous quarter and by 18% YoY
The debt is 100% less than the equity
MAIA's equity has surged by 155% since the previous quarter but it has dropped by 54% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.